



**PuriCore Announces Appointment
of
Andrea Holtzman Drucker as General Counsel and Corporate
Secretary**

MALVERN, PENNSYLVANIA, and STAFFORD, UK, November 13, 2006 -- PuriCore plc ("PuriCore") (London Stock Exchange: PURI), the developer of a novel, safe technology that mimics the human body's natural anti-microbial, hypochlorous acid, today announces that the company has appointed attorney Andrea ("Andi") Holtzman Drucker as Senior Vice President, General Counsel, and Corporate Secretary effective immediately.

Ms. Drucker joins PuriCore from Novavax, Inc., a publicly traded vaccine company, where she has been acting General Counsel since December 2005. Ms. Drucker previously served as interim Associate General Counsel at publicly listed Auxilium Pharmaceuticals, Inc. At both companies Ms. Drucker was responsible for commercial transactions focusing on business development, as well as corporate governance, intellectual property and regulatory matters associated with the U.S. Food and Drug Administration.

Prior to joining Auxilium, Ms. Drucker spent 17 years at FMC Corporation in a number of roles including six years as Group Counsel of FMC BioPolymer, a global performance chemicals business providing ingredients and excipients to the pharmaceutical industry. A graduate of Cornell University and the University of Pennsylvania School of Law, Ms. Drucker began her career as an attorney with the Philadelphia law firm Ballard Spahr Andrews & Ingersoll.

Greg Bosch, the Chief Executive of PuriCore, commented:

"I am delighted that Andi is joining the PuriCore management team. With her background in life sciences at both large, well-established and smaller organizations, she brings invaluable experience that will add tremendous value to PuriCore's current and developing businesses."

FOR FURTHER INFORMATION:

PuriCore plc

Greg Bosch, Chief Executive Officer
Keith A. Goldan, Chief Financial Officer

T: +1 (484) 321-2701

Financial Dynamics

John Gilbert
Ben Brewerton

T: +44 (0) 20 7831 3113

ABOUT PURICORE PLC

PuriCore is a life sciences company focused on the development and commercialization of its proprietary technology that mimics the production by the human body of its natural anti-microbial, hypochlorous acid. Hypochlorous acid is highly effective at killing pathogens such as bacteria, viruses and fungal spores and yet is safe and environmentally friendly. PuriCore's solutions have applications in a wide range of markets where it is important to control microbial contamination. These markets include medical device disinfection, food safety, dental equipment, hospitality, water safety, wound management and other applications intended to limit the spread of infectious disease, including major global disease threats such as Tuberculosis, MRSA, *E. coli*, norovirus, HIV, polio virus, *Helicobacter pylori* and Legionella.

PuriCore markets a portfolio of branded systems which produce hypochlorous acid solutions on-site at a customer's location from water, electricity and common salt. These solutions are generated at a range of concentrations and at a nearly neutral pH range similar to the human body. They are effective as soaks, sprays, mists and in other forms.

PuriCore is headquartered in Malvern, Pennsylvania and has offices in Stafford, England.

To receive additional information on the Company, please visit our Web site at <http://www.puricore.com>, which does not form part of this press release.

END